FDA expands use of Genentech's Actemra to include polyarticular JIA

Genentech received approval from the FDA to market Actemra, or tocilizumab, for children 2 and older with active polyarticular juvenile idiopathic arthritis. The drug, a humanized interleukin-6 receptor antagonist, can be given alone or with methotrexate. The approval was based on data from a late-stage trial showing that the drug improved symptoms in children with the condition.

View Full Article in:

Medscape (free registration) · BioPharm International online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Paralegal
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA